Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114858) titled 'A Single-Arm, Single-Center, Prospective Phase II Clinical Study of Stephania Longa and Jiezai Rice Combined with Sintilimab in Advanced Driver Gene-Negative, PD-L1-Positive NSCLC Patients Who Failed First-Line Immunotherapy' on Dec. 18, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Hainan General Hospital
Condition:
PD-L1-positive, driver mutation-negative advanced non-small cell lung cancer (NSCLC) with failure of first-line immunotherapy (as monotherapy or in combination with chemotherapy)
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-06-1...